ACHL - Enrollment underway in Achilles Therapeutics' Phase I/IIa lung cancer study

Achilles Therapeutics (ACHL) announces that the first patient in U.S. has been enrolled in its Phase I/IIa CHIRON clinical trial, evaluating the safety, tolerability, and activity of clonal neoantigen T cell (cNeT) therapy as a single dose in adult patients with advanced metastatic non-small cell lung cancer ((NSCLC)). CHIRON is expected to recruit approx. 40 patients. The primary objective is to assess the safety and tolerability of cNeT.Clinical efficacy will be evaluated as a secondary measure. Additional data evaluating cNeT persistence, phenotype, and functionality will be reviewed while also exploring potential biomarkers of clinical activity and factors affecting response.

For further details see:

Enrollment underway in Achilles Therapeutics' Phase I/IIa lung cancer study